Drug Approval | March 06, 2022
USFDA approves expanded use of Bristol Myers Opdivo
The approval marks the first-and-only immunotherapy-based treatment for use before surgery for non-small cell lung cancer
The approval marks the first-and-only immunotherapy-based treatment for use before surgery for non-small cell lung cancer
The company also reported the issuance of an additional U.S. patent covering the drug, and the filing of a continuation patent application intended to expand patent coverage to other facets of the drug
ChipCytometry delivers single-cell targeted spatial proteomics for complex whole-tissue analysis of the tumour microenvironment, as well as deep immune profiling for applications in immunology, neuroscience, and infectious disease
It plans launch various other health monitoring tools for smartphones, making existing devices obsolete
Ten new Ayush hospitals and one Ayurvedic college will be set up in Nagaland and Mizoram
Novel delivery of established growth and neurotrophic factors enables local, sustained release for greater efficacy
Ovarian cancer is one of the most difficult cancers to treat. It is typically not detected until later stages, and about 70 percent of patients will have recurrence after an initial treatment, which is often fatal
This has further strengthened its manufacturing presence in the United States of America
If approved, Opdivo plus chemotherapy would be the first neoadjuvant immunotherapy-based option for patients with resectable non-small cell lung cancer in the U.S.
This innovative biomanufacturing technology will help to deliver cost-effective viral production that is unmatched in the industry
Subscribe To Our Newsletter & Stay Updated
